| Pair Name | Luteolin, Erastin | ||
| Phytochemical Name | Luteolin (PubChem CID: 5280445 ) | ||
| Anticancer drug Name | Erastin (PubChem CID: 11214940 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Luteolin, Erastin | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Ferroptosis | |||
| Gene Regulation | Down-regulation | Expression | GPX4 | hsa2879 |
| Up-regulation | Expression | HIC1 | hsa3090 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| SW480 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0546 | |
| In Vivo Model | The mice were subjected to subcutaneously injection with HCT116 cells (5×10⁶, suspended in PBS) in each right flank, the mice were treated every 2 days for eight times. | |||
| Result | These results clearly demonstrated that luteolin acts synergistically with erastin and renders colon cancer cells vulnerable to ferroptosis through the HIC1-mediated inhibition of GPX4 expression, which may act as a promising therapeutic strategy. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression. Free Radic Biol Med. 2023 Nov 1;208:530-544. doi: 10.1016/j.freeradbiomed.2023.09.014. | Click |
